← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Pulmotect, Inc
Houston, TX
$7,025,093
Total funding
7
Grants
Funding over time
peak $2M · FY2011–17$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$7,025,093 · 7
By mechanism
R44$6,270,701 · 4
R43$754,392 · 3
Investigators at Pulmotect, Inc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Preventing and treating RSV pneumonia in immunocompromised cancer patients$999,372
R44 · FY2016 · HL
Expanding the Market and Success Rates for Myeloablative Cancer Treatments Using PUL-042, an Innate Immune Stimulant$998,771
R44 · FY2017 · HL
Expanding the Market and Success Rates for Myeloablative Cancer Treatments Using PUL-042, an Innate Immune Stimulant$998,771
R44 · FY2016 · HL
Rapidly boosting innate immunity in the lungs to protect against pneumonia$997,525
R44 · FY2013 · AI
Preventing asthma exacerbations by reducing viral respiratory infections$985,628
R44 · FY2014 · HL
Expanding the Market and Success Rates for Myeloablative Cancer Treatments Using PUL-042, an Innate Immune Stimulant$982,488
R44 · FY2015 · HL
Rapidly boosting innate immunity in the lungs to protect against pneumonia$308,146
R44 · FY2014 · AI
Preventing asthma exacerbations by reducing viral respiratory infections$301,296
R43 · FY2012 · HL
Boosting the innate immune system of the lungs to prevent and treat respiratory v$231,348
R43 · FY2014 · HL
Rapidly boosting innate immunity in the lungs to protect against pneumonia$221,748
R43 · FY2011 · AI